Altasciences , a fully integrated CRO/CDMO providing comprehensive solutions for early-stage drug development, is pleased to announce a strategic collaboration with Evidence Matters , a pioneer in data processing and document generation for clinical trials.
This partnership combines Altasciences’ practical experience in drug development with Evidence Matters’ innovative, patent-pending text engineering technology – a groundbreaking development that enables near-deterministic accuracy in the creation of regulatory documents by reducing variability and improving the quality, consistency, and speed of documentation.
Evidence Matters’ RegulatoryFlow platform (“RegFlow”) and specialized services consolidate clinical data and documents, simplifying workflows and accelerating the work of key life sciences professionals, from medical writers to regulatory specialists.
“We look forward to collaborating with Evidence Matters to jointly develop technologies that will directly improve the quality and efficiency of regulatory document creation,” said Nicole Maciolek, Vice President, Research Services at Altasciences . “Through this partnership, we will not only implement AI but actively shape its future as an essential tool in the life sciences.”
Also Read: Tempus AI Acquires Paige to Advance AI in Precision Medicine
Altasciences is heavily involved in this partnership by providing real-world training data and conducting user testing to help ensure the technology meets the needs of the teams on-site. This collaboration also underscores Altasciences’ ongoing commitment to using artificial intelligence to drive innovation, optimize complex processes, and deliver better outcomes for sponsors and patients alike.
“With Text Engineering, we’re going a step beyond automation and entering a new era of precision and consistency,” said Dr. Ofer Avital, Founder and Director of Evidence Matters. “The impact on regulatory documentation, from timelines to accuracy, is transformative. Tests comparing manual workflows with RegulatoryFlow showed that RegulatoryFlow completely eliminates table translation errors, which occur in approximately one-third of the tables in life sciences regulatory documents. Furthermore, the turnaround time for converting TFL files to Word files was reduced by more than 50%.”
Dr. Avital continued, “Unlike traditional enterprise platforms that require long implementation times, RegulatoryFlow integrates seamlessly with existing Microsoft Word workflows. This enables rapid deployment in weeks rather than months, meeting the needs of medical writers directly where they work.”
Together, Altasciences and Evidence Matters are redefining the way clinical trials are conducted and documented, helping sponsors move faster and more confidently from candidate selection to clinical proof of concept and beyond.
Source: Businesswire
